Role of Checkpoint Inhibitors in Oncology
Alessandro Inno
(Thanks to Dr. Alessandro Inno for sharing this presentation through cardioncology.org)
Download presentation in PDF format
PRESENTATION TOPICS
(presentation content in English language)
-
The Cancer-Immunity Cycle
-
Immune Checkpoints
-
T-cell targets for immunoregulatory antibody therapy
-
Blockade of CTLA-4 and PD-1/PD-L1 Signaling
-
Cancer Immunotherapy
-
FDA Approval Timeline of Checkpoint Inhibitors
-
5-yr Follow-Up of Nivolumab in previously treated advanced NSCLC (CA209-003 study)
-
How to raise the bar in Immuno-Oncology?
-
-
PD-L1 as a Biomarker in advanced NSCLC
-
Towards Personalized Medicine in Immuno-Oncology
-
IO-based Combinations
-
IO/CTx combination in NSCLC
-
-
-
Toxicity of Checkpoint Inhibitors
-
Immune-Related Adverse Events
-
Incidence of irAEs with anti-CTLA4 and anti-PD1/PDL1 agents
-
Toxicity of Combinations
-
In Summary, Checkpoint Inhibitors…
Download presentation in PDF format